Alcoholic Hepatitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Alcoholic Hepatitis – Drugs In Development, 2024 report and make more profitable business decisions.
Alcoholic hepatitis is inflammation of the liver caused by excessive alcohol consumption over a long period of time. Symptoms include changes in appetite, dry mouth, weight loss, yellowing of the skin or eyes (jaundice), fever, and fatigue. Risk factors include alcohol use, obesity, and genetic factors. Treatment includes corticosteroids and liver transplant.
The Alcoholic Hepatitis drugs in development market research report provide comprehensive information on the therapeutics under development for Alcoholic Hepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Alcoholic Hepatitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 20 molecules, with 19 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Alcoholic Hepatitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Alcoholic Hepatitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Alcoholic Hepatitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Akaza Bioscience LtdAldeyra Therapeutics Inc
Alfasigma SpA
DURECT Corp
Evive Biotech
GeneToBe LLC
Hepatx Corp
HighTide Therapeutics Inc
Intercept Pharmaceuticals Inc
Korro Bio Ops Inc
Novartis AG
Odan Laboratories Ltd
Pattern Therapeutics
Pleiogenix
Rejuvenation Technologies Inc
Seal Rock Therapeutics Inc
Surrozen Inc
UMass Chan Medical School
Vectus Biosystems Ltd
Zydus Lifesciences Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Alcoholic Hepatitis reports